Journal: Experimental & Molecular Medicine

Article Title: Dynamics of chromatin accessibility governing Gd-IgA1 synthesis in B cells associated with IgA nephropathy

doi: 10.1038/s12276-025-01505-1

Figure Lengend Snippet: a Transfection of the DAKIKI cell line with adenoviruses containing coding sequences for KLF4, followed by western blot analysis to assess target protein expression. b , c Collection of culture supernatant 3 days after transfection for IgA1 ( b ) and Gd-gA1 ( c ) ELISA analysis ( n = 6). d Transfection of EBV-immortalized B cells with adenoviruses containing coding sequences for KLF4, followed by western blot analysis for target protein expression. e , f Collection of culture supernatant from EBV-immortalized B cells 3 days after transfection for IgA1 ( e ) and Gd-gA1 ( f ) ELISA analysis ( n = 6). g Electroporation of synthetic siRNA targeting the human KLF4 gene or control siRNA into the DAKIKI cell line. h , i Collection of culture supernatant from the DAKIKI cell line 3 days after electroporation for IgA1 ( h ) and Gd-gA1 ( i ) ELISA analysis ( n = 6). j , Electroporation of synthetic siRNA targeting the human KLF4 gene or control siRNA into the EBV-immortalized B cell lines. k , l Collection of culture supernatant from EBV-immortalized B cell lines 3 days after electroporation for IgA1 ( k ) and Gd-gA1 ( j ) ELISA analysis ( n = 6). Bars represent the mean ± s.e.m. * P < 0.05, ** P < 0.01.

Article Snippet: Spot-urine samples were collected, and the levels of urinary albumin and creatinine were measured using urinary albumin ELISA kits (Elabscience) and creatinine ELISA kits (Elabscience), respectively.

Techniques: Transfection, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay, Electroporation, Control

Journal: Drug Design, Development and Therapy

Article Title: Nanomedical strategy to prolong survival period, heighten cure rate, and lower systemic toxicity of S180 mice treated with MTX/MIT

doi: 10.2147/DDDT.S113804

Figure Lengend Snippet: Serum ALT, AST, and Cr levels of the mice treated with CMCNa, MTX/MIT, and MSNN−MTX/MIT. Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; Cr, creatinine; CMCNa, sodium carboxyl methyl cellulose; MTX, methotrexate; MIT, mitoxantrone; MSNN, amino group-modified mesoporous silica nanoparticles; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase.

Article Snippet: The separated plasma was used to measure plasma levels of alanine transaminase (ALT) and aspartate transaminase (AST) according to the manufacturer’s instructions (AST/GOT testing kit, ALT/GPT testing kit; JCBIO Co., Nanjing, People’s Republic of China).

Techniques: Modification

Journal: The Journal of Clinical Investigation

Article Title: Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis

doi: 10.1172/JCI180062

Figure Lengend Snippet: ( A ) TSP-1 protects FB from cleavage by FD. FB was incubated with FD, C3b, and varying concentrations of TSP-1. Subsequently, FB and its cleavage products were visualized by Coomassie blue staining. Graph on the right illustrates band intensity of FB and its cleavage products. ( B ) TSP-1 inhibits cleavage of C3 by the alternative complement pathway C3 convertase. C3 convertase was generated by incubating C3(H2O) with FB and FD, followed by the addition of C3 in the presence or absence of TSP-1 or FH. As a positive control, CVF C3 convertase (CVF + FB + FD) was utilized. The graph on the right depicts the band intensity of C3-α′ chain. Lanes were run on the same gel but were noncontiguous. Data are shown as mean ± SD. ( C ) TSP-1 inhibits cleavage of C5. Cobra venom factor (CVF) convertase (CVFBb) was generated and added to C5 preincubated with FH, eculizumab, MFHR1, or TSP-1. The amount of released C5a was quantified by ELISA. Data are shown as mean ± SD. ANOVA was used with Dunnett’s multiple-comparison test. ( D ) TSP-1 inhibits the formation of MAC. Sheep erythrocytes were premixed with C7 (9 nM), C8 (7 nM), and C9 (15 nM). BSA, eculizumab, MFHR1, or TSP-1 (1.3 μM each) were preincubated with C5b-6 (0.7 nM) and then added to the erythrocytes. Data are shown as mean ± SD of 3 independent experiments; ** P ≤ 0.01, *** P ≤ 0.01; 1-way ANOVA was used with Tukey’s post hoc test for comparison against control.

Article Snippet: The following ELISAs and sample dilutions were used in this study: mouse albumin ELISA kit (1:500.000, Crystal Chem, 80630), mouse creatinine (Cr) ELISA kit (1:10, AFG Scientific, EK734005 ), mouse complement C3 ELISA kit (1:300, Abcam, AB157711 ), mouse Cit H3 ELISA kit (1:10, Biorbyt, ORB1496437), mouse C5a ELISA kit (1:25, Antikoerper Online, ABIN6720057), and mouse TSP-1 (THBS1) ELISA kit (1:60, Biozol, ABX575980).

Techniques: Incubation, Staining, Generated, Positive Control, Combined Bisulfite Restriction Analysis Assay, Enzyme-linked Immunosorbent Assay, Comparison, Control